Lechleiter’s surgery to repair heart goes as planned

Eli Lilly and Co. CEO John Lechleiter underwent a scheduled surgery Monday for a heart defect, and the repair to the aorta is functioning as intended, the Indianapolis-based drugmaker said.

Chief Financial Officer Derica Rice has been filling in as CEO while Lechleiter recuperates.

Lilly said on May 6 that Lechleiter, 59, would undergo an operation to correct a dilated aorta. The condition, which wasn’t causing any symptoms, occurs when there is a bulge or ballooning of the larger artery that carries blood from the heart through the chest and abdomen, according to the National Institutes of Health. Lechleiter’s condition was found during an unrelated test, the company had said.

“Dr. Lechleiter’s surgeons have advised us that surgery went as expected,” said Kristine A. Courtney, senior director of Lilly’s corporate health services. “Dr. Lechleiter is recovering and will be closely monitored by the medical staff over the next several days.”

Lilly shares were up 21 cents, to $65 each, in early trading Tuesday.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: IBJ is now using a new comment system. Your Disqus account will no longer work on the IBJ site. Instead, you can leave a comment on stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Past comments are not currently showing up on stories, but they will be added in the coming weeks. Please note our updated comment policy that will govern how comments are moderated.